Extended Data Fig. 7: Establishment of the hCD19+ Eμ-Myc B-ALL/Lymphoma mouse model for assessing hCD19-targeted mCAR-T therapy. | Nature Biomedical Engineering

Extended Data Fig. 7: Establishment of the hCD19+ Eμ-Myc B-ALL/Lymphoma mouse model for assessing hCD19-targeted mCAR-T therapy.

From: Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

Extended Data Fig. 7

a) Experimental setup and timeline and enumeration of circulating leukemic cells (n = 4 animals). C57BL/6 albino mice were lymphodepleted (L.D.) and injected with 0.5x106 hCD19+ Eμ-Myc cells. Peripheral blood was collected on days 0, 6, 8, 14 and 19. Created in BioRender. Ma, L. (2025) https://BioRender.com/xd8q66t (b) Representative IVIS imaging of Eμ-Myc albino mice at day 4. (c) Overall survival of untreated Eμ-Myc mice in this manuscript (n = 40). (d) FMC63 IgG binding to primary mouse B cells as monitored using flow cytometry. An anti-mouse CD19 IgG clone 6D5 was included as a control. (e) Schematics of tandem αFITC-FMC63-mCAR-T. (f) Cytotoxicity of FMC63 mCAR-T or tandem αFITC-FMC63-mCAR-T against WT (murine CD19+) or hCD19+ Eμ-Myc mouse B-ALL cells. A luciferase-based assay was used for assessing cell killing by CAR-T (see Methods). Error bars show mean±95% CI for A, mean ± s.d. (n = 2 for WT Eμ-Myc, n = 3 for hCD19+ Eμ-Myc) for F.

Source data

Back to article page